MARCKS and melanoma: Our study reveals that MARCKS is a critical mediator of enhanced metastasis in BRAF inhibitor-resistant melanoma cells and thus a reasonable, novel antimetastatic therapeutic target in patients with BRAF inhibitor-resistant melanoma.